

Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

Francesco Schettini^{a,b,c,1,*}, Sergio Venturini^{d,1}, Mario Giuliano^e, Matteo Lambertini^{f,g}, David J. Pinato^{h,i}, Concetta Elisa Onesti^j, Pietro De Placido^e, Nadia Harbeck^k, Diana Lüftner^l, Hannelore Denys^m, Peter Van Damⁿ, Grazia Arpino^e, Khalil Zaman^o, Giorgio Mustacchi^p, Joseph Gligorov^q, Ahmad Awada^r, Mario Campone^s, Hans Wildiers^t, Alessandra Gennariⁱ, Vivianne Tjan-Heijnen^u, Rupert Bartsch^v, Javier Cortes^{w,x,y,z,aa}, Ida Paris^{bb}, Miguel Martín^{cc}, Sabino De Placido^e, Lucia Del Mastro^{f,g}, Guy Jerusalem^{dd}, Giuseppe Curigliano^{ee}, Aleix Prat^{a,b,c,ff,gg}, Daniele Generali^{hh,ii,*}

^a Translational Genomics and Targeted Therapies in Solid Tumors, 08036 Barcelona, Spain

^b Department of Medical Oncology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain

^c Department of Medicine, University of Barcelona, 08036 Barcelona, Spain

^d Department of Economic and Social Sciences, Catholic University of Sacred Heart - Cremona Campus, 26100 Cremona, Italy

^e Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy

^f Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, 16132 Genova, Italy

^g Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy

^h Division of Cancer, Department of Surgery and Cancer, Imperial College London, SW7 2AZ London, UK

ⁱ Department of Translational Medicine, Università del Piemonte Orientale "A. Avogadro", 28100 Novara, Italy

^j Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy

^k Breast Center, Department OB&GYN and CCCLMU, LMU University Hospital, 81377 Munich, Germany

^l Department of Hematology, Oncology and Tumor Immunology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany

^m Department of Medical Oncology, UZ Gent, 9000 Gent, Belgium

ⁿ Oncology Department, University Hospital Antwerp (UZA), 2650 Edegem, Belgium

^o Oncology Department, Lausanne University Hospital CHUV, 1011 Lausanne, Switzerland

^p Medical Oncology, University of Trieste, 34127 Trieste, Italy

^q Department of Medical Oncology, Tenon Hospital, Institut Universitaire de Cancérologie AP-HP, Sorbonne University, 75004 Paris, France

^r Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Bruxelles, Belgium

^s Medical Oncology, Institut de Cancérologie de l'Ouest-Pays de la Loire, 44800 Saint-Herblain, France

^t Department of General Medical Oncology, University Hospital Leuven, 3000 Leuven, Belgium

^u Medical Oncology, Maastricht University Medical Center (MUMC), 6229 HX Maastricht, Netherlands

^v Division of Oncology, Department of Medicine 1, Medical University of Vienna, 1090 Vienna, Austria

^w International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain

^x Medica Scientia Innovation Research (MedSIR), Barcelona, Spain

^y Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA

^z Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain

^{aa} Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain

^{bb} Department of Woman and Child Health and Public Health, Woman Health Area, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

^{cc} Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, 28007 Madrid, Spain

^{dd} Medical Oncology, CHU Sart Tilman Liège and University of Liège, 4000 Liège, Belgium

* Corresponding authors at: Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), CELLEX Building, C. Casanova 143, 1st floor, sector A, 08036 Barcelona, Spain (Francesco Schettini). Head of the Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Viale Concordia 1, 26100, Cremona (Italy) (Daniele Generali).

E-mail addresses: schettini@clinic.cat (F. Schettini), sergio.venturini@unicatt.it (S. Venturini), m.giuliano@unina.it (M. Giuliano), matteo.lambertini@unige.it (M. Lambertini), david.pinato@imperial.ac.uk (D.J. Pinato), nadia.harbeck@med.uni-muenchen.de (N. Harbeck), diana.lueftner@charite.de (D. Lüftner), hannelore.denys@ugent.be (H. Denys), peter.vandam@uza.be (P. Van Dam), grazia.arpino@unina.it (G. Arpino), khalil.zaman@chuv.ch (K. Zaman), mail@mustacchioncology.it (G. Mustacchi), joseph.gligorov@tnn.aphp.fr (J. Gligorov), ahmad.awada@bordet.be (A. Awada), mario.campone@ico.unicancer.fr (M. Campone), hans.wildiers@uzleuven.be (H. Wildiers), alessandra.gennari@uniupo.it (A. Gennari), vcg.tjan.heijnen@mumc.nl (V. Tjan-Heijnen), rupert.bartsch@meduniwien.ac.at (R. Bartsch), jacortes@vhio.net (J. Cortes), ida.paris@policlinicogemelli.it (I. Paris), mmartin@geicam.org (M. Martín), deplacid@unina.it (S. De Placido), lucia.delmastro@hsanmartino.it (L. Del Mastro), g.jerusalem@chuliege.be (G. Jerusalem), giuseppe.curigliano@ieo.it (G. Curigliano), alprat@clinic.cat (A. Prat), dgeneral@units.it (D. Generali).

<https://doi.org/10.1016/j.ctrv.2022.102468>

Received 3 July 2022; Received in revised form 20 September 2022; Accepted 22 September 2022

Available online 28 September 2022

0305-7372/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

^{ee} Istituto Europeo di Oncologia, IRCCS ed Università di Milano, 20141 Milano, Italy

^{ff} Oncology Department, IOB Institute of Oncology, Quiron Group, 08023 Barcelona, Spain

^{gg} SOLTI Cooperative Research Group, 08008 Barcelona, Spain

^{hh} Department of Medicine, Surgery and Health Sciences, University of Trieste, 34127 Trieste, Italy

ⁱⁱ Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, 26100 Cremona, Italy

ARTICLE INFO

Keywords:

Triple negative breast cancer
Bayesian network meta-analysis
Therapeutic algorithm
PD-L1
BRCA
PARP inhibitors
Immunotherapy
Sacituzumab govitecan
Trastuzumab deruxtecan
HER2-low
Pembrolizumab

ABSTRACT

Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately. We also estimated separate treatment rankings for the first and subsequent lines according to each endpoint, based on (surface under the cumulative ranking curve) SUCRA values. No first-line treatment was associated with superior PFS and OS than paclitaxel ± bevacizumab. Platinum-based polychemotherapies were generally superior in terms of ORR, at the cost of higher toxicity.. PARP-inhibitors in germline-*BRCA1/2*-mutant patients, and immunotherapy + chemotherapy in PD-L1-positive mTNBC, performed similar to paclitaxel ± bevacizumab. In PD-L1-positive mTNBC, pembrolizumab + chemotherapy was better than atezolizumab + nab-paclitaxel in terms of OS according to SUCRA values. In second/further-lines, sacituzumab govitecan outperformed all other treatments on all endpoints, followed by PARP-inhibitors in germline-*BRCA1/2*-mutant tumors. Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in terms of PFS and OS after sacituzumab govitecan, according to SUCRA values. Moreover, comparisons with sacituzumab govitecan, talazoparib and olaparib were not statistically significant. The most effective alternatives or candidates for subsequent lines were represented by nab-paclitaxel (in ORR), capecitabine (in PFS) and eribulin (in PFS and OS).

Introduction

Triple negative breast cancer (TNBC) represents approximately 10–15 % of all breast tumors and is defined by the absence of endocrine receptors (ER) and HER2 gene overexpression/amplification [1]. Metastatic TNBC (mTNBC) remains an incurable disease with unfavorable prognosis [2]. However, the scenario is quickly changing. 10.6–41.9 % TNBC harbor a germline mutation in the homologous recombination repair (HRR) genes *BRCA1/2* [3]. In these cases, following positive results from respective pivotal trials, it is now possible to administer the PARP-inhibitors (PARPi) olaparib or talazoparib in first or further lines [4,5]. Additionally, the TNT phase III first-line trial recently demonstrated that carboplatin was more effective than the standard of care docetaxel in germline *BRCA1/2*-mutant (g*BRCA*-mut) mTNBC [1]. Intriguingly, in the same trial, in a broader condition of HRR deficiency (HRD), none of the 2 drugs was superior to the other [1]. Recently, two randomized phase III studies showed that PD-L1 positive (+) mTNBC (though selected with different methodologies) derive benefit from the addition of an anti-PD-L1/PD-1 immune-checkpoint inhibitor (ICI) to upfront chemotherapy (CT) [6,7]. However, the majority of mTNBC are PD-L1-negative (40–80 %) and germline *BRCA1/2*-wild type (g*BRCA*-wt) (60–90 %) [3,8,9], thus being only manageable with mono- or poly-CT, with the possibility (only in Europe) to use a first-line combination of bevacizumab with either paclitaxel or capecitabine [10,11].

Importantly, the novel anti-TROP2 antibody-drug conjugate (ADC) sacituzumab govitecan provided unprecedented overall response rates (ORR), progression-free survival (PFS) and overall survival (OS) benefit in heavily pretreated mTNBC [12,13], quickly leading to a US Food and Drug Administration (FDA) approval in this subset. Although preliminary, similar findings have been recently observed with the novel ADC trastuzumab deruxtecan (T-DXd) in the subset of TNBC with low expression levels of HER2 [14,15].

In this complex and changing scenario, uncertainties exist on whether and when to prefer single-agent over multi-agent treatments and most regimens have not undergone head-to-head comparisons. Also,

the role of platinum-based regimens is unclear and therapeutic sequencies uncertain [11,16,17]. To date, only network meta-analyses (NMA) provides a methodologically reliable statistical framework to indirectly compare treatments that have never been confronted in head-to-head studies, given that such therapies have been compared to at least one common comparator [18,19]. NMA also allows to determine the amount of agreement between the results obtained when different linking treatments are used; it can incorporate results from direct comparisons, to account for both direct and indirect evidences at the same time, and it can provide a rank ordering of the interventions [18,19].

Therefore, we conducted a systematic literature search to identify all phase II/III randomized controlled trials (RCT) published in the last 20 years comparing all CT and target therapies (TT) in metastatic HER2-negative breast cancer (BC) and carried out multiple Bayesian NMA to define the best therapeutic options for mTNBC according to treatment line.

Methods

Search strategy and selection criteria

We performed a systematic literature search on Pubmed® and CENTRAL to identify all phase II/III RCT published between 01/01/2000 and 30/06/2020 comparing all CT and TT in metastatic HER2-negative BC. The time span was selected to both retrieve studies more uniformly conceived and presented, and include all currently available and most promising therapeutic options. The full search query is reported in the [Supplementary Methods](#). Articles relevant to the topic published between July 2020 and June 2022 were manually included in the networks before conducting final analyses. Online archives of the San Antonio Breast Cancer Symposium, European Society for Medical Oncology (ESMO)'s Congress, ESMO Breast Congress and American Society of Clinical Oncology (ASCO)'s Annual Meeting were also consulted. No language restrictions were adopted. Records had to be preferably full papers, however, for each trial where only an abstract was available and results were adequately provided, the study was included in our analyses. In case of more publications for the same study, the most

¹ co-first authors for equal contribution.

updated one was considered. Two independent reviewers (FS and MG) carried out the systematic revision of the literature and a third one (DG) was consulted in case of controversy. Some cross-references from main international guidelines were also included.

Endpoints

We aimed at identifying the best therapeutic option for the first-line and second/further (advanced) lines, separately, according to efficacy/activity and safety. PFS was the primary endpoint whereas ORR, OS and safety were secondary endpoints.

Data extraction

To be included, a publication had to provide at least the data for one of the three endpoints of this study (detailed response rates and/or hazard ratios [HR] of PFS and/or OS). In case HR for Time-to-Progression (TTP) instead of PFS were provided, TTP was considered for the analysis. TTP and PFS are very similar endpoints, which have been frequently mixed-up in other previously published NMA [20–22]. The HR and associated 95 % confidence intervals (CI) for OS and PFS/TTP were extracted from each paper. The number of patients achieving a partial or complete response as their best response according to treatment arm were extracted to calculate the ORR.

Data concerning the following variables were also extracted from all the studies: full publication reference, publication year, line of treatment, phase of the trial, investigated treatments, single center vs multicenter studies, follow-up period (months), total number of patients, proportion of patients with ER + BC, median age, age range, proportion of patients with PD-L1+, gBRCA-mut and altered PI3K/PTEN pathway, as well as proportion of visceral, lung, liver and bone metastases, and main grade (G)3–5 adverse events (AEs).

Several adjustments regarding data extraction need to be disclosed. Firstly, when a study set in first and further lines presented with a result for the entire population enrolled and separate results for the first line and for the following, results according to treatment lines were extracted. Secondly, three trials specifically enrolled patients with gBRCA-mut tumors [4,5,23]. Therefore, our results concerning the therapeutic agents administered within these studies have to be intended only for the specific subgroup of gBRCA-mut TNBC. Third, the same three studies presented separate aggregate data for TNBC and ER + tumors, although such results were not provided according to treatment line. To better estimate the therapeutic efficacy in the first and subsequent lines, we preferred to include results according to treatment line, although a proportion of ER + BC was comprised in these estimates. Fourth, the studies of pembrolizumab and atezolizumab included both patients with and without PD-L1+ tumors [7,24–26]. Considering that such drugs have been FDA and/or European Medicine Agency (EMA)-approved only in mTNBC with a PD-L1 combined positive score (CPS) ≥ 10 % or PD-L1 levels ≥ 1 % according to the Ventana SP142 assay, respectively, only results for these subpopulations have been included. As a consequence, our results concerning the therapeutic agents administered within these studies have to be intended only for the specific subgroup of PD-L1+ mTNBC, with PD-L1 positivity defined according to the relative trials' assays. Finally, AKT-inhibitors ipatasertib in Kim et al. 2017 and capivasertib in Schmid et al. 2019 were tested in TNBC with and without alterations in PIK3CA, AKT1 or PTEN, whilst the former was tested in Dent et al. 2021 only in PIK3CA/PTEN/AKT-altered mTNBC [27–29]. For ipatasertib, which failed to prove a significant benefit transferrable to the clinical practice, the results for the intention-to-treat (ITT) trials' population were included. Conversely, capivasertib was included for the obtained results in the PIK3CA/PTEN/AKT-altered population, a subset with a potential approval; although results from the phase III trial are required to draw definitive conclusions. Finally, in order to include some trials in the networks, some links had to be forced. More specifically, the capecitabine-containing treatment of physician's choice (TPC) arms

from Litton et al. and Robson et al. were linked to the capecitabine arm of Harbeck et al. to include olaparib and talazoparib in the first-line networks [4,5,30]. The CT arm of Cortes et al., which included also paclitaxel, and the taxane-containing arm of Takashima et al. were linked to weekly paclitaxel and the CT arm of Von Minckwitz et al. was considered as a TPC arm, allowing its inclusion in the second/further-lines networks [25,31,32]. Additionally, TPC arms did not differ too much among different trials, therefore they were always linked together, whenever possible.

Data analysis

A Bayesian NMA framework was used for each endpoint and for each treatment line for a total of 6 networks, i.e. first-line and advanced lines networks of PFS/TTP, ORR and OS, respectively [18,19,33].

We also provided a ranking of treatments based on the surface under the cumulative ranking curve (SUCRA). The SUCRA values range from 0 to 100 %. The higher the SUCRA value, and the closer to 100 %, the higher the likelihood that a therapy is in the top rank; the closer to 0 the SUCRA value, the more likely that a therapy is in the bottom rank [34].

The parameters of the different models (HR of PFS/TTP and OS with 95 % credible intervals [CrI] and OR for ORR with 95 %CrI) were estimated using a Markov Chain Monte Carlo method as implemented in the WinBUGS software package [33]. For all the analyses, the WinBUGS sampler, using three chains, was run for 1,000,000 iterations that were discarded as 'burn-in', and the model was run for a further 2,000,000 iterations on which inferences were based. A thinning rate of 100 iterations was used to reduce autocorrelation of the sampled values, thus leaving 20,000 iterations per chain to use for estimation and inference. Convergence of the chains was confirmed by the Gelman-Rubin statistic and by inspection of the trace plots [35,36]. For each NMA, the model providing the best fit to the data between random- and fixed-effect was chosen based on the Deviance Information Criterion (DIC). The DIC provides a measure of model fit that penalizes model complexity. The model with the lowest DIC was considered the model providing the best fit to the data, otherwise, wherever DIC values were similar (difference of < 5) a fixed-effect model was preferred [33]. For the NMA of the HR, we assumed that the logHR were normally distributed with the logHR mean equaling the true logHR observed in each study and the variance equaling the observed variability in each study.

We used a vague flat (i.e., uniform) prior distribution for between-study standard deviation τ . Moreover, as for the correlations between the random effects for each trial, we adopted the standard approach to set this correlation equal to 0.5 [37]. We used a common between-study variance parameter τ^2 for all studies.

The PRISMA guidelines for NMA were followed [38]. Inconsistency of the results was explored, as recommended [38–40]. For all treatment line networks according to each endpoint, an inconsistency model was obtained by omitting the consistency equations. Then, for each endpoint, the consistency and inconsistency models were compared in terms of goodness of fit by using their relative DIC [39,40]. A difference of less than 5 points was considered to be not significant.

All the analyses were performed with WinBUGS version 1.4.3 and the results were processed using R version 4.2.0 [33,41]. All the equations adopted had been published elsewhere and adapted for our analyses [37]. Internal validity of eligible studies was assessed with Review Manager version 5.4 according to the Cochrane guidelines [42].

The study protocol was registered on PROSPERO (ID: CRD42020211971).

Results

Overall, 139 studies were included in our networks for a total of 118 different therapeutic regimens for the first-line and 33 for the following lines (all references in [Supplementary Methods](#)). The study selection process is summarized in [Supplementary Fig. 1](#). First-line networks

included 125 RCT whilst advanced-line networks included 33 RCT (Supplementary Tables 1–2 and Supplementary Figs. 2–7). The first-line PFS, OS and ORR networks were based on trial-level data deriving from 31,203, 22,848 and 36,015 patients, respectively. Advanced-line PFS, OS and ORR networks were based on trial-level data deriving from 7,185, 6,467 and 11,321 patients, respectively. Eighteen (56.2 %) advanced-line studies included a proportion of first-line patients and were also incorporated in first-line networks. Ninety-two (73.6 %) first-line studies also included ER + metastatic BC (MBC) (minimum–maximum [min–max] range of ER + MBC patients in the included studies: 14 % – 91 %). Twenty-one (63.6 %) advanced-line studies involved ER + MBC (min–max range: 26.1 % – 83.3 %), as well. Considering all included studies, the median proportion of patients with ER + MBC *per* treatment arm was 59.5 % (interquartile range [IQR] of 35.3 % – 74.0 %) and endocrine therapy (ET) for the metastatic disease had been administered before study treatments in 37 % of the cases in at least a proportion of patients *per* treatment arm. Four (2.9 %) trials explicitly included a proportion of PD-L1+ tumors [6,7,26,43], 5 (3.6 %) trials included, exclusively or in part, gBRCA-mut MBC [1,4,5,13,23], and 3 (2.2 %) trials included patients with PIK3CA/PTEN/AKT-altered tumors [27–29]. Overall, 49 (35.3 %) studies

evaluated TT, with or without CT while the remaining 91 (64.7 %) only compared different CT regimens or schedules. Study characteristics are extensively reported in Supplementary Tables 1–2.

To graphically visualize the results, paclitaxel + bevacizumab was chosen as the reference treatment for the first-line, being a potentially good compromise between mono-CT and poly-CT, while capecitabine was the reference for the advanced lines, as in numerous RCT.

Inconsistency and consistency models' DIC for each network are reported in the Supplementary Methods. A marginally significant inconsistency was observed only for the first-line ORR network (a difference between the DIC of consistency and inconsistency models of 6.49).

First-line networks

A total of 92 different regimens were compared for PFS/TTP. None was deemed to be significantly superior to paclitaxel + bevacizumab, including poly-CT regimens such as anthracycline/taxane combinations or other anthracycline-based regimens and taxanes + platinum agents (Fig. 1). At the same time, paclitaxel + bevacizumab was not likely to be superior to any first-line mono-CT, such as weekly paclitaxel, pegylated




Fig. 1. Forest plot of all first-line regimens compared to paclitaxel + bevacizumab in terms of PFS/TTP. The figure has been split in two panels (A and B) to improve its readability. The forest plot includes the log hazard ratios (HR) of each treatment *versus* paclitaxel + bevacizumab. Central dots represent posterior medians; thin lines represent 95 % credible intervals (CrI), while thicker ones represent 80 % CrI. Log scale was adopted to graphically represent the 95 % CrI. The first column of values on the right reports the log HR with 95 % CrI, the second column reports HR with 95 % CrI. Statistically significant results according to Bayesian posterior medians and 95 % credible intervals are highlighted by asterisks. 5-FU: 5-fluorouracil; AC: doxorubicin + cyclophosphamide; ATEZO: atezolizumab; AXI: axitinib; BEVA: bevacizumab 10 mg/kg IV q2w; BEVA 7.5: bevacizumab 7.5 mg/kg IV q3w; BEVA 15: bevacizumab 15 mg/kg IV q3w; BMF: bendamustine + methotrexate + 5-FU; CAPE: capecitabine; CAPE LD: capecitabine low dose/metronomic; CAPI: capivasertib; CAPI: capivasertib; CYC: cyclophosphamide; CARBO: carboplatin; CIS: cisplatin; CME: cyclophosphamide + mitoxantrone + etoposide; CMF: cyclophosphamide + methotrexate + 5-FU; CT: chemotherapy; DOC: docetaxel; DOXO: doxorubicin 75 mg/m² q3w; DOXO 60: doxorubicin 60 mg/m² q3w; EC: epirubicin + cyclophosphamide; EPI: epirubicin; ERI: eribulin; EVE: everolimus; FAC: 5-FU + doxorubicin + cyclophosphamide; FEC: 5-FU + epirubicin 75 mg/m² + cyclophosphamide q3w; FEC 100: 5-FU + epirubicin 100 mg/m² + cyclophosphamide q3w; FEC 50: 5-FU + epirubicin 50 mg/m² + cyclophosphamide q3w; GEM: gemcitabine; INI: iniparib; IPA: ipatasertib; IXA: ixabepilone; LONI: lonidamine; MITO C: mitomycin C; MITOX: mitoxantrone; MMM: mitoxantrone + mitomycin C + methotrexate; MOT: motesinib; NAB-PAC: nab-paclitaxel 260/300 mg/m² q3w; NAB-PAC 100 qw: nab-paclitaxel 100 mg/m² q3/4w; NAB-PAC qw: nab-paclitaxel 125/130/150 mg/m² q3/4w; NPLD: non-pegylated liposomal doxorubicin; OLA: olaparib; PAC within schedules and PAC q3w: paclitaxel 175 mg/m² q3w; PAC 210: paclitaxel 210 mg/m² q3w; PAC 250: paclitaxel 250 mg/m² q3w; PAC qw: paclitaxel 80/90 mg/m² q3/4w; PEMBRO: pembrolizumab; PEMBRO + CT: pembrolizumab + nab-paclitaxel/paclitaxel/carboplatin + gemcitabine; PLD: pegylated liposomal doxorubicin 50 mg/m² IV q4w; PLD 40 mg: pegylated liposomal doxorubicin 40 mg/m² IV q4w; PLD 60 mg: pegylated liposomal doxorubicin 60 mg/m² IV q4w; RAMU: ramucirumab; SCT: stem cell transplant; SOR: sorafenib; SUN: sunitinib; TALAZO: talazoparib; TMZ: temozolomide; TREB3: trebananib 3 mg/kg qw; TREB10: trebananib 10 mg/kg qw; TRILA: trilaciclib 240 mg/m² d1,8 IV q3w; TRILA 1,2,8,9: Trilaciclib 240 mg/m² d1,2,8,9 IV q3w; VELI: veliparib; VINFLU: vinflunine; VNR: vinorelbine; IV: intravenous; d: day; qw: weekly schedule; q2w: biweekly schedule; q3w: threeweekly schedule; q3/4w: 3 weeks out of 4 schedule; q4w: every-4-weeks schedule; ->: followed by; DD: dose dense; HD: high dose; TI: time intensive; *: statistically significant results.

liposomal doxorubicin (PLD) or nab-paclitaxel (Fig. 1). Sixty-four regimens included in the PFS/TTP analysis were also comparable in terms of OS with consistent results (Fig. 2). In contrast, when compared to other 117 regimens, paclitaxel + bevacizumab was likely to be significantly associated with superior ORR than several poly-CT regimens like cyclophosphamide + methotrexate + 5-fluorouracil (CMF) (odds ratio [OR]: 6.57, 95 % credible intervals [CrI]: 2.05–21.63), FEC (OR: 4.44, 95 %CrI: 1.33–15.23), ixabepilone + capecitabine (OR: 3.45, 95 %CrI: 1.02–12.03) or capecitabine + bevacizumab (OR: 2.47, 95 %CrI: 1.08–5.73) (Supplementary Fig. 8). The reference regimen was associated with lower ORR only when compared to docetaxel + cisplatin (OR: 0.13, 95 %CrI: 0.02–0.82). Additionally, paclitaxel + bevacizumab was

likely to be significantly superior to several mono-CT, like PLD (OR: 6.89, 95 %CrI: 1.30–36.67) or capecitabine (OR: 5.47, 95 %CrI: 1.89–16.17) (Supplementary Fig. 8).

Notably, similar results were observed with weekly paclitaxel, as well as with atezolizumab + nab-paclitaxel or pembrolizumab + CT in PD-L1+ TNBC, and with olaparib or talazoparib in gBRCA-mut TNBC (data not shown). Direct comparisons based on indirect evidence of atezolizumab + nab-paclitaxel vs pembrolizumab + CT or talazoparib vs olaparib did not show significant differences, respectively (Supplementary Table 3).




Fig. 2. Forest plot of all first-line regimens compared to paclitaxel + bevacizumab in terms of OS. The forest plot includes the log hazard ratios (HR) of each treatment versus paclitaxel + bevacizumab. Central dots represent posterior medians; thin lines represent 95 % credible intervals (CrI), while thicker ones represent 80 % CrI. Log scale was adopted to graphically represent the 95 % credible intervals. The first column of values on the right reports the log HR with 95 % credible intervals, the second column reports HR with 95 % credible intervals. Statistically significant results according to Bayesian posterior medians and 95 % credible intervals are highlighted by asterisks. 5-FU: 5-fluorouracil; ATEZO: atezolizumab; BEVA: bevacizumab 10 mg/kg IV q2w; BEVA 7.5: bevacizumab 7.5 mg/kg IV q3w; BEVA 15: bevacizumab 15 mg/kg IV q3w; CAPE: capecitabine; CAPE LD: capecitabine low dose/metronomic; CAPI: capivasertib; CYC: cyclophosphamide; CARBO: carboplatin; CIS: cisplatin; CMF: cyclophosphamide + methotrexate + 5-FU; DOC: docetaxel; DOXO: doxorubicin 75 mg/m² q3w; DOXO 60: doxorubicin 60 mg/m² q3w; ERI: eribulin; EVE: everolimus; FEC: 5-FU + epirubicin 75 mg/m² + cyclophosphamide q3w; FEC 100: 5-FU + epirubicin 100 mg/m² + cyclophosphamide q3w; FEC 50: 5-FU + epirubicin 50 mg/m² + cyclophosphamide q3w; GEM: gemcitabine; INI: iniparib; IPA: ipatasertib; IXA: ixabepilone; NAB-PAC: nab-paclitaxel 260/300 mg/m² q3w; NAB-PAC 100 qw: nab-paclitaxel 100 mg/m² q3/4w; NAB-PAC qw: nab-paclitaxel 125/130/150 mg/m² q3/4w; NPLD: non-pegylated liposomal doxorubicin; OLA: olaparib; PAC within schedules and PAC q3w: paclitaxel 175 mg/m² q3w; PAC qw: paclitaxel 80/90 mg/m² q3/4w; PLD: pegylated liposomal doxorubicin 50 mg/m² q4w; SOR: sorafenib; SUN: sunitinib; TALAZO: talazoparib; TMZ: temozolomide; TRILA: Trilaciclib 240 mg/m² d1,8 IV q3w; TRILA 1,2,8,9: Trilaciclib 240 mg/m² d1,2,8,9 IV q3w; VELI: veliparib; VINFLU: vinflunine; VNR: vinorelbine; qw: weekly schedule; q2w: biweekly schedule; q3w: threeweekly schedule; q3/4w: 3 weeks out of 4 schedule; q4w: every-4-weeks schedule; →: followed by; DD: dose dense; HD: high dose.

Advanced lines networks

Seventeen regimens entered the advanced-line network of PFS/TTP. Compared to capecitabine, sacituzumab govitecan (HR: 0.51, 95 %CrI: 0.36–0.72), ixabepilone + capecitabine (HR: 0.75, 95 %CrI: 0.64–0.88), and talazoparib (HR: 0.67, 95 %CrI: 0.46–0.97) were likely to be superior. Conversely, commonly used alternatives like eribulin and vinorelbine, or olaparib in gBRCA-mut tumors, showed comparable results (Fig. 3). T-DXd in HER2-low TNBC showed a numerically similar result to sacituzumab govitecan, although not significant (Fig. 3).

Fifteen of the 16 previous regimens entered the network of OS. Only sacituzumab govitecan was significantly superior to capecitabine (HR: 0.52, 95 %CrI: 0.38–0.72) (Fig. 4).

When considering ORR, 33 treatments were comparable. Among clinically relevant regimens, only sacituzumab govitecan (OR: 3.34, 95 %CrI: 1.16–9.45) and ixabepilone + capecitabine (OR: 3.19, 95 %CrI: 2.24–4.61) were associated with better ORR than capecitabine (Supplementary Fig. 9). Importantly, sacituzumab govitecan showed the best survival results, being significantly superior to many common therapies,

including eribulin and ixabepilone + capecitabine (in PFS and OS), vinorelbine (in PFS), pembrolizumab in PD-L1+ mTNBC (in PFS and OS), olaparib and talazoparib in gBRCA-mut tumors (in OS) (not shown). No significant difference was observed in PFS/TTP and OS between sacituzumab govitecan and T-DXd in HER2-low tumors, as well as between olaparib and talazoparib in gBRCA-mut patients (Supplementary Table 3).

Treatment rankings based on SUCRA and safety

We estimated separate rankings for the first and subsequent lines based on SUCRA values (Supplementary Figs. 10–11). For practical purposes, we refined the rankings by including only the currently US National Comprehensive Cancer Network (NCCN)-recommended [10] and/or FDA/EMA-approved treatments, as of June 2022 (Table 1). Nevertheless, the ranking includes also T-DXd, which is likely to be approved in the near future for HER2-low TNBC.

A formal comparison of toxicities could not be carried out due to the heterogeneity of reporting side effects across trials. However, we




Fig. 3. Forest plot of all advanced lines regimens compared to capecitabine in terms of PFS/TTP. The forest plot includes the log hazard ratios (HR) of each treatment versus capecitabine. Central dots represent posterior medians; thin lines represent 95 % credible intervals (CrI), while thicker ones represent 80 % CrI. Log scale was adopted to graphically represent the 95 % CrI. The first column of values on the right reports the log HR with 95 % CrI, the second column reports HR with 95 % CrI. Statistically significant results according to Bayesian posterior medians and 95 % credible intervals are highlighted by asterisks. BEVA: bevacizumab 10 mg/kg q2w; CAPE: capecitabine; ENZA: enzastaurin; ERI: eribulin; GEM: gemcitabine; IXA: ixabepilone; OLA: olaparib; PEMBRO: pembrolizumab; RAMU: ramucirumab; T-DXd: trastuzumab deruxtecan; SAC GOV: sacituzumab govitecan; SOR: sorafenib; SUN: sunitinib; TALAZO: talazoparib; TPC: treatment of physician's choice (mostly CAPE, ERI, or VNR); VINFLU: vinflunine; VNR: vinorelbine; qw: weekly schedule; q2w: biweekly schedule; q3w: three weekly schedule; *: statistically significant results.




Fig. 4. Forest plot of all second/further-lines regimens compared to capecitabine in terms of OS. The forest plot includes the log hazard ratios (HR) of each treatment *versus* capecitabine. Central dots represent posterior medians; thin lines represent 95 % credible intervals (CrI), while thicker ones represent 80 % CrI. Log scale was adopted to graphically represent the 95 % credible intervals. The first column of values on the right reports the log HR with 95 % credible intervals, the second column reports HR with 95 % credible intervals. Statistically significant results according to Bayesian posterior medians and 95 % credible intervals are highlighted by asterisks. BEVA: bevacizumab 10 mg/kg q2w; CAPE: capecitabine; ENZA: enzastaurin; ERI: eribulin; IXA: ixabepilone; OLA: olaparib; PEMBRO: pembrolizumab; RAMU: ramucirumab; SAC GOV: sacituzumab govitecan; SOR: sorafenib; SUN: sunitinib; TALAZO: talazoparib; TPC: treatment of physician’s choice (mostly CAPE, ERI, or VNR); VINFLU: vinflunine; VNR: vinorelbine; qw: weekly schedule; q2w: biweekly schedule; q3w: threeweekly schedule; *: statistically significant result.

extensively described the proportion of G3-5 AEs observed for each regimen in $\geq 2\%$ of study patients (Supplementary Tables 4–5). As expected, combination CT presented with the highest proportion of moderate/severe AEs. Nevertheless, G3-5 neutropenia and leucopenia were relatively frequent also with mono-CT. Doxorubicin, docetaxel, vinorelbine, paclitaxel and gemcitabine were associated with the highest rates of severe alopecia, as like capecitabine with hand-foot syndrome and doxorubicin with stomatitis and febrile neutropenia. Anthracycline-based regimens, excluding pegylated and non-pegylated liposomal doxorubicin, were typically associated with cardiotoxicity. Bevacizumab-containing regimens typically showed proteinuria and hypertension. Although ICI-based combinations (pembrolizumab + CT and atezolizumab + nab-paclitaxel) are usually associated with immune-related AEs, including thyroiditis, pneumonitis, skin alterations and colitis, G3-5 rates of such toxicities were not observed, except for pneumonitis, hypo/hyperthyroidism and skin reactions (all $< 2\%$). PARPi were characterized by an overall better toxicity profile than mono-CT, except for partially comparable hematologic toxicities. Finally, sacituzumab govitecan and T-DXd presented with a chemo-like toxicity profile, with diarrhea, nausea/vomiting, hematotoxicity and fatigue as most frequent moderate/severe AEs. Both drugs can

frequently induce alopecia (46.0 % and 37.7 %) and T-DXd was associated with interstitial lung disease/pneumonitis ($< 20\%$ cases), although the vast majority of cases was mild or moderate [13,15].

Risk of bias analysis

Internal validity of eligible studies was assessed with a risk of bias (RoB) analysis as recommended by the Cochrane Handbook for Systematic Reviews of Interventions [42]. There were no specific concerns regarding 5/9 RoB domains (Supplementary Fig. 12). However, the RoB was high in approximately half trials included with respect to blinding of participants and personnel and outcome assessments, as well as regarding the selective reporting bias (Supplementary Figs. 12–13).

Discussion

We performed multiple Bayesian NMA to identify the best treatment for the first and subsequent lines of mTNBC, in terms of PFS/TTP, OS and ORR. We found that among the most commonly adopted first-line regimens, there were no substantial differences in terms of PFS/TTP and OS whereas paclitaxel + bevacizumab was associated with better ORR than

Table 1
Ranking of available regimens according to treatment line.

FIRST-LINE								
Treatment	SUCRA	PFS/TTP Ranking	Treatment	SUCRA	OS Ranking	Treatment	SUCRA	ORR Ranking
DOC + CIS	0.9135	1	NAB-PAC q3w + CARBO	0.7660	1	DOC + CIS	0.9800	1
CIS + PAC q3w	0.8174	2	PEMBRO + CT	0.7355	2	CIS + PAC q3w	0.8896	2
NAB-PAC q3w + CARBO	0.7537	3	DOC + CIS	0.7268	3	NAB-PAC qw + ATEZO	0.7326	3
DOXO + DOC	0.7147	4	CARBO + GEM	0.6948	4	PAC qw + BEVA	0.6980	4
NAB-PAC qw + ATEZO	0.6696	5	CAPE + BEVA	0.6797	5	GEM + DOC	0.6893	5
CIS + GEM	0.6535	6	TALAZO	0.6638	6	NAB-PAC q3w + CARBO	0.6833	6
PAC qw + BEVA	0.6430	7	ERI	0.6455	7	PAC qw	0.6802	7
NPLD + CYC	0.6369	8	IXA q3w + CAPE	0.6369	8	CAPE + PAC q3w	0.6779	8
AC	0.6365	9	OLA	0.6259	9	DOXO + DOC	0.6198	9
DOXO + PAC q3w	0.6291	10	PAC qw + BEVA	0.6060	10	EPI + PAC q3w	0.6126	10
FEC 100	0.6184	11	S1	0.5940	11	CAPE + DOC	0.5936	11
VNR + CAPE	0.6158	12	PAC qw	0.5683	12	OLA	0.5766	12
PEMBRO + CT	0.6132	13	CAPE	0.5649	13	NAB-PAC q3w	0.5722	13
TALAZO	0.6080	14	PLD	0.5567	14	DOXO + PAC q3w	0.5632	14
CAPE + DOC	0.5907	15	DOXO 60	0.5165	15	NAB-PAC qw	0.5455	15
OLA	0.5764	16	FEC 100	0.5089	16	CARBO + PAC q3w	0.5453	16
CARBO + GEM	0.5613	17	NAB-PAC 100 qw + ATEZO	0.4895	17	GEM + PAC q3w	0.5258	17
FAC	0.5250	18	FEC	0.4522	18	TALAZO	0.5214	18
GEM + DOC	0.4998	19	CIS + GEM	0.4145	19	NPLD + CYC	0.5189	19
CAPE + BEVA	0.4942	20	VNR + CAPE	0.4068	20	VNR + CAPE	0.5110	20
GEM + PAC q3w	0.4853	21	CARBO + PAC q3w	0.3852	21	EPI + DOC	0.5087	21
EPI + PAC q3w	0.4785	22	CAPE LD + DOC	0.3815	22	AC	0.4845	22
NAB-PAC qw	0.4760	23	CMF	0.3641	23	EC	0.4255	23
CAPE + PAC q3w	0.4755	24	GEM + PAC q3w	0.3563	24	DOXO	0.4250	24
IXA q3w + CAPE	0.4472	25	NPLD	0.3419	25	DOC	0.4065	25
EC	0.4437	26	GEM + DOC	0.3327	26	NAB-PAC q3w	0.4048	26
CARBO + PAC q3w	0.4124	27	NAB-PAC qw	0.3120	27	VNR + GEM	0.3835	27
FEC	0.4094	28	CAPE + DOC	0.2896	28	CARBO	0.3770	28
NAB-PAC q3w	0.4074	29	PAC q3w	0.2578	29	CAPE + BEVA	0.3593	29
DOXO	0.3914	30	DOC	0.1806	30	FAC	0.3499	30
PLD	0.3855	31	-	-	-	CARBO + GEM	0.3327	31
PAC qw	0.3837	32	-	-	-	CIS + GEM	0.3052	32
EPI + DOC	0.3569	33	-	-	-	FEC 100	0.2981	33
PAC q3w	0.3247	34	-	-	-	PAC q3w	0.2787	34
DOC	0.3134	35	-	-	-	IXA + CAPE	0.2696	35
CAPE	0.3124	36	-	-	-	VNR	0.2479	36
CMF	0.2661	37	-	-	-	PLD	0.1979	37
-	-	-	-	-	-	FEC	0.1880	38
-	-	-	-	-	-	CAPE	0.1420	39
-	-	-	-	-	-	CMF	0.1070	40

SECOND/FURTHER LINES								
Treatment	SUCRA	PFS/TTP Ranking	Treatment	SUCRA	OS Ranking	Treatment	SUCRA	ORR Ranking
SAC GOV	0.965	1	SAC GOV	0.9595	1	CAPE + DOC	0.8082	1
T-DXd*	0.8581	2	T-DXd*	0.9110	2	NAB-PAC q3w	0.7993	2
TALAZO	0.8158	3	ERI	0.6487	3	IXA q3w + CAPE	0.7518	3
OLA	0.7555	4	PEMBRO	0.6443	4	SAC GOV	0.7504	4
IXA q3w + CAPE	0.7481	5	IXA q3w + CAPE	0.5962	5	PAC qw	0.7151	5
GEM + VNR	0.4781	6	TALAZO	0.5361	6	CAPE LD + DOC	0.7088	6
CAPE	0.4263	7	OLA	0.4366	7	DOC	0.6328	7
ERI	0.3281	8	CAPE	0.3711	8	T-DXd*	0.5516	8
VNR	0.1346	9	-	-	-	GEM + DOC	0.5359	9
PEMBRO	0.1152	10	-	-	-	GEM + VNR	0.5038	10
-	-	-	-	-	-	PAC q3w	0.4709	11
-	-	-	-	-	-	OLA	0.4519	12
-	-	-	-	-	-	DOC	0.4167	13
-	-	-	-	-	-	CAPE + SUN	0.4060	14
-	-	-	-	-	-	TALAZO	0.3862	15
-	-	-	-	-	-	CAPE	0.3704	16
-	-	-	-	-	-	ERI	0.3532	17
-	-	-	-	-	-	VNR	0.3251	18
-	-	-	-	-	-	PEMBRO	0.2539	19

CMF: cyclophosphamide + methotrexate + 5-FU; 5-FU: 5-fluorouracil; BEVA: bevacizumab; ATEZO: atezolizumab; EPI: epirubicin; FEC: 5-FU + epirubicin + cyclophosphamide; FAC: 5-FU + doxorubicin + cyclophosphamide; DOXO: doxorubicin; DOC: docetaxel; PAC: paclitaxel; PLD: pegylated liposomal doxorubicin; NPLD: non-pegylated liposomal doxorubicin; CYC: cyclophosphamide; TALAZO: talazoparib; OLA: olaparib; IXA: ixabepilone; CAPE: capecitabine; GEM: gemcitabine; VNR: vinorelbine; ERI: eribulin; PEMBRO: pembrolizumab; NAB-PAC: nab-paclitaxel; CT: chemotherapy; CIS: cisplatin; CARBO: carboplatin; AC: doxorubicin + cyclophosphamide; EC: epirubicin + cyclophosphamide; SAC GOV: sacituzumab govitecan; ERI: eribulin; T-DXd: trastuzumab deruxtecan; LD: low dose; q3w: three weekly schedule; qw: weekly schedule; *: although still not approved, T-DXd is the new standard of care for HER2-low breast cancer and might enter quickly the therapeutic armamentarium also for this subset of triple negative tumors.

numerous mono-CT and several poly-CT, with less G3-5 AEs compared to CT combinations. Docetaxel + cisplatin was the only regimen significantly favored in terms of ORR, at the cost of higher toxicities (Figs. 1-2, Supplementary Fig. 8, Table 1, Supplementary Tables 4-5). These results, taken together with the available evidence, despite conflicting results on its potential OS benefit [20,44-48], support paclitaxel + bevacizumab as a suitable first-line option. At the same time, the lack of a clear superiority in survival endpoints, especially in comparison to mono-CT options, makes the combination of paclitaxel with bevacizumab a valuable regimen mostly when a rapid and/or potent tumor shrinkage is the required therapeutic goal (e.g. high tumor burden, visceral crisis). In this case, the better safety profile of this regimen compared to those of poly-CT plays in favor of paclitaxel + bevacizumab. To note, this regimen is no longer available in the USA and, where available (e.g. Europe), its higher costs compared to mono-CTs and numerous poly-CT regimens should be properly taken into account at the moment of therapeutic decision-making.

Interestingly, platinum-based regimens, especially in combination with taxanes, resulted in very high SUCRA values for all endpoints, but their potential benefits should be weighed against their higher toxicities (e.g. nausea/vomiting, peripheral neuropathy, hemato-toxicity) and patients' inclination to receive the appropriate supportive care, when required [49-51].

A viable alternative in patients unfit for/unwilling to receive poly-CT, or with low tumor burden, is the use of mono-CT. The best-ranked single-agents in terms of both PFS and OS appeared to be weekly paclitaxel and PLD (Table 1). Single-agent carboplatin is another option, with many mono-CTs being not significantly superior to it in terms of ORR (data not shown), including taxanes (coherently with the TNT trial) [1]. Yet, it could not be included in the PFS and OS networks, limiting the evidence to support it as a clear standard. The choice among one of those drugs should be properly discussed and adapted to patients' preferences, especially with regard to their different toxicity profile and different administration schedule.

Notably, talazoparib and olaparib in gBRCA-mut patients were among the highest ranked available treatments, without superior mono-CTs (Table 1). Conversely, many multiagent regimens, although not selectively tested in gBRCA-mut patients, were associated to better outcomes (Table 1). Therefore, PARPi might reasonably represent an optimal first-line option in gBRCA-mut cases when no combinations are strictly required. Notably, signals of activity beyond BRCA1/2 mutant TNBC might lead to an expansion of their therapeutic indication, if further confirmed [52-55]. Importantly, recently published positive results on adjuvant olaparib in gBRCA-mut early-stage TNBC already lead to FDA approval in this subset [56]. Whether this might affect the efficacy of first-line PARPi in case of relapse will be a matter of debate in the next years.

Regarding PD-L1+ mTNBC, no treatment was significantly superior to atezolizumab + nab-paclitaxel for all the 3 endpoints investigated and to pembrolizumab + CT in terms of PFS/TTP and OS (data not shown). These combinations also showed a relatively favorable and manageable toxicity profile compared to numerous poly-CT regimens (Supplementary Tables 4-5). Overall, based on these results and considering that ICI + CT regimens are limited to the first-line setting, atezolizumab + nab-paclitaxel or pembrolizumab + CT might be the preferred upfront treatment for PD-L1+ mTNBC. Importantly, the comparison between the two regimens in our study was not statistically significant but pembrolizumab + CT was favored over more first-line regimens and obtained the best position in the OS SUCRA-based ranking. In addition, atezolizumab + nab-paclitaxel pivotal trial's result was formally negative due to its hierarchical testing plan [7]. Furthermore, following the manufacturer's request, the FDA (but not EMA) also recently withdrew its indication for atezolizumab in this setting [24,57,58].

In case of concomitant PD-L1+gBRCA-mut tumors, the evidence is still too scarce to draw any meaningful conclusion. Yet, PARPi can be administered also in advanced lines, while, at present, ICI-based therapy

cannot. Interestingly, an ongoing phase II/III RCT of pembrolizumab + olaparib vs pembrolizumab + CT after induction with pembrolizumab + CT in mTNBC will provide additional important insights [59].

Another open question is whether to prefer first-line platinum agents or PARPi in PD-L1-negative/gBRCA-mut TNBC, considering that BRCA1/2 dysfunction has been associated with increased response to platinum agents [60]. Our results suggest that platinum-based regimens in unselected TNBC (potentially including also gBRCA-mut tumors) are likely better than PARPi in gBRCA-mut tumors on all 3 endpoints (Table 1). Importantly, roughly 20 % and 30 % of patients receiving talazoparib and olaparib in their pivotal trials, respectively, had been pretreated with platinum agents [4,5]. Hence, the sequencing might not impair PARPi's efficacy, although those subpopulations had not progressed on platinum [4,5]. Nevertheless, the evidence to unequivocally support either strategy is still insufficient. The different toxicity profile among these agents may help guiding treatment choice according to individual patient characteristics and preferences.

Finally, as observable in the full treatment rankings (Supplementary Fig. 10), paclitaxel + capivasertib, in PIK3CA/PTEN/AKT-altered TNBC, and carboplatin + gemcitabine + CDK4/6-inhibitor trilaciclib, in unselected mTNBC, proved to be particularly effective. In both cases, confirmatory phase III trials are ongoing and results eagerly awaited [61,62], especially after the unexpected negative results of the IPATunity130 phase III trial of first-line paclitaxel + ipatasertib [28].

Concerning advanced lines, sacituzumab govitecan was associated to the best PFS, OS and ORR results (Figs. 3-4, Supplementary Fig. 9, Table 1). These data strongly support sacituzumab govitecan being the preferred second-line in mTNBC. At the same time, olaparib and talazoparib in gBRCA-mut tumors were favored among all other treatments in terms of PFS/TTP, with no difference between the two PARPi on all endpoints (Fig. 3, Table 1, Supplementary Table 3). Hence, in the absence of sacituzumab govitecan, a PARPi might represent the preferable second-line in gBRCA-mut mTNBC, if not previously used. In the subset of HER2-low tumors, representing ~ 37 % of all TNBC [14], T-DXd provided also extremely promising results, being one of the best options in terms of all 3 endpoints. The overall comparisons led to a better positioning of sacituzumab govitecan in SUCRA-based rankings. Still, a direct comparison between the two ADCs did not show significant differences. No significant difference was also observed with PARPi, but overall results, especially in OS, were in favor of T-DXd. However, considering the low number of patients treated with T-DXd, these results have to be taken carefully. T-DXd might be well positioned either after sacituzumab govitecan or before/right after PARPi in gBRCA-mut HER2-low TNBC. Direct comparisons in RCT, especially between the two ADCs should be pursued to draw more definitive conclusions.

Subsequent most effective mono-CT were represented by nab-paclitaxel (ORR), capecitabine (PFS/TTP) and eribulin (PFS/TTP, OS) (Table 1). The former could not enter survival networks but solid efficacy data concur in supporting its use also in taxane-pretreated patients [63,64]. Whether to administer one or the others is a decision that should be individualized based on toxicity profile, drug delivery method (oral for capecitabine vs intravenous for eribulin and nab-paclitaxel), previous therapies, patients' clinical conditions and preferences. Conversely, not many poly-CT could enter our networks and the ones that could, did not show any significant advantage on all endpoints to justify their use in advanced lines compared to mono-CT, providing also their worse toxicity profile.

Finally, single-agent pembrolizumab appeared to be another valuable option in advanced lines. However, the results hereby reported are based on PD-L1+ mTNBC, whereas it is currently FDA-approved in patients with high microsatellite instability/mismatch repair deficiency or high tumor mutational burden [65,66].

This study has several limitations to consider. First, several assumptions and simplifications fully disclosed in the Methods section (including forcing some links), were required to include the majority of the most relevant therapeutic options and should be carefully taken into

account when evaluating this study results. Second, we did not report publication bias since the approaches developed to assess this type of bias in NMA are challenging and still present limitations that make their effectiveness often debated [67]. However, our analysis includes most of the available literature on the topic, somewhat mitigating the impact of publication bias. Third, some results are based on specific biomarker-defined subpopulations (i.e. PD-L1+, gBRCA-mut, HER2-low or PIK3CA/PTEN/AKT-altered), hence they cannot be generalized to the totality of mTNBC. However, considering that these subgroups represent a limited proportion of TNBC and their concomitant presence is uncommon, it is likely that no RCT will ever be conducted comparing the most appropriate biomarker-based treatments within such nested subgroups. Moreover, no evidences are available to conduct specific biomarker-restricted networks. In this scenario, this study provides unique results that might be valuable for clinicians. Furthermore, while sufficient evidence suggest novel biomarker-based treatments are not effective in all TNBC patients, there is no biologic rationale or published evidence supporting lack of efficacy of previous standard treatments in biomarker-based subgroups. Fourth, ~72 % of studies included also ER+/HER2-negative MBC. Given that mTNBC are usually considered to be more CT-sensitive than ER+/HER2-negative tumors [11,20], it is possible that the efficacy of several regimens might have been diluted in favor of some treatments tested in TNBC-restricted trials. At the same time, in 40 % of study treatment arms, the ER positivity proportion was < 50 %, meaning that the TN population was overall highly represented. Furthermore, in such studies, ET for the metastatic disease had been administered before CT in more than 1/3 cases, further reducing the proportion of fully endocrine-sensitive ER + MBC, which are potentially

less sensitive to CT than endocrine pre-treated tumors [11,17,68]. To note, a certain heterogeneity in the proportion of patients with visceral/non-visceral/brain metastases among included studies was also present and should be taken into account when considering results. Fifth, the highest risks of bias were observed in the domains of the performance bias, blinding of outcome assessment and selective reporting bias. Concerning the latter, since our study was focused on 3 endpoints (i.e. PFS, OS and ORR) we decided to adopt a comprehensive approach in the RoB analysis by taking into account all endpoints concomitantly. However, the limit of this approach is that at least one of the 3 endpoints was not published in many cases (usually OS), for reasons attributable to the same study design (roughly a third were phase II RCT). However, the primary endpoint (i.e. PFS) was only partially affected by this issue (~74 % first-line and ~ 82 % advanced-line studies reported PFS data) and results for the three different endpoints were substantially coherent among them. Regarding blinding of outcome and performance bias, the risk was high because approximately half studies were not blinded. At a closer look, this was often justified by different ways of drug administration that made it impossible, unethical or useless to apply any blinding procedure. Those issues could not be overcome and sub-analysis on the restricted casuistry of studies with no blinding bias was unfeasible because of the impossibility of closing meaningful networks. Nevertheless, most of these studies led to the approval of regimens and schedules commonly used in clinical practice. Importantly, no substantial inconsistency was observed (Supplementary Methods). Finally, we point out that NMA share the same limitations of standard pairwise meta-analyses [69,70], with the addition of a set of specific assumptions, including transitivity and consistency, on which a lot of




Fig. 5. Proposed therapeutic algorithms for the first and following lines. mTNBC: metastatic triple negative breast cancer; wt: wild-type; mut: mutant; gBRCA: germline BRCA1 and/or 2; CT: chemotherapy; ICI: immune-checkpoint inhibitors (atezolizumab or pembrolizumab); PLD: pegylated liposomal doxorubicin; NPLD: non-pegylated liposomal doxorubicin; neg.: negative; +: positive; PARPi: PARP inhibitor; TMB high: tumor mutational burden ≥ 10 mutations/megabase; MSI-H: high microsatellite instability (≥ 30 % mutations); dMMR: dysfunctional mismatch repair; 1: indicate the same advanced lines algorithm of PD-L1+/gBRCA-mut, independently from PD-L1 status; 2: indicate the same advanced lines algorithm of PD-L1+/gBRCA-wt, independently from PD-L1 status; *: pembrolizumab should be preferred over atezolizumab, where available, considering the more methodologically solid results in its pivotal trial and the better position in the SUCRA-based overall survival ranking. Moreover, atezolizumab is no longer approved in the USA for this setting; #: still not approved in Europe, but recently FDA-approved for HER2-low metastatic breast cancer, irrespective of hormone receptor status; §: if not previously administered in first-line with chemotherapy. The algorithm is based on the results published in Table 1, Figs. 1-4, Supplementary Figs. 8-9, Supplementary Tables 3-5 and results not shown for space reasons. All data were then interpreted according to the available literature reviewed plus the most updated American and European Society for Clinical/Medical Oncology (ASCO and ESMO) and US National Comprehensive Cancer Network (NCCN) guidelines.

research is still ongoing [37,71,72].

In conclusion, despite limitations, this is the first study comparing all available systemic treatments for the management of mTNBC, providing timely and methodologically reliable results. In this perspective, we propose a consensus therapeutic algorithm resumed in Fig. 5, based on our original data, literature review and main international guidelines to support daily-practice therapeutic decision-making [10,11,17,73].

CRediT authorship contribution statement

Drs F. Schettini, D. Generali, M. Giuliano and prof. S. Venturini had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr F. Schettini and prof S. Venturini contributed equally to this work and served as co-first authors.

Concept and design: Drs F. Schettini, D. Generali.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Drs F. Schettini, D. Generali, A. Prat, G. Curigliano, M. Giuliano, G. Jerusalem, R. Bartsch and prof S. Venturini.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Prof S. Venturini.

Obtained funding: N/A.

Administrative, technical, or material support: N/A.

Supervision: Dr D. Generali.

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Giuliano, Arpino and De Placido S have declared honoraria from Roche, Pfizer, Astra-Zeneca, Novartis, Celgene, Eli Lilly, Amgen, and Eisai, outside of the submitted work.

Dr Lambertini has declared personal fees (advisory role and/or speaker honoraria) from Roche, Takeda, Sandoz, Eli Lilly, Pfizer, AstraZeneca, Novartis Exact Sciences and Ipsen, outside of the submitted work.

Dr Bartsch has declared honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Roche, consulting or advisory role for AstraZeneca, Daiichi, Eisai, Eli Lilly, MSD Oncology, Novartis, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, research funding from Daiichi-Sankyo, travel, accommodations, expenses from Roche, Pfizer, outside of the submitted work.

Dr Pinato has received lecture fees from ViiV Healthcare and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, Eisai, Roche, and Astra Zeneca; research funding (to institution) from MSD and BMS, outside of the submitted work.

Dr Harbeck has declared stocks and other ownership interests in the West German Study Group, honoraria from Roche, Novartis, Daiichi-Sankyo, Amgen, Pfizer, Exact Sciences, AstraZeneca, Pierre Fabre, SeaGen; consulting or advisory role for Roche/Genentech, Novartis, Pfizer, Eli Lilly, Sandoz, Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme, Sandoz, SeaGen, Pierre Fabre and research funding to institution from Roche/Genentech, Eli Lilly, Merck Sharp & Dohme, outside of the submitted work.

Dr Lüftner has received honoraria from Amgen, AstraZeneca, Celgene, Eisai, Genomic Health, Eli Lilly, Loral, MSD, Novartis, Pierre Fabre, Pfizer, Tesaro, Teva, outside of the submitted work.

Dr Denys has reported consulting fees (advisory role) paid to her institution by Pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly, Novartis, Amgen, Tesaro; grants from Research Funding institutional Roche; and other fees (travel, accommodations, expenses) by Pfizer, Roche, PharmaMar, Teva, AstraZeneca, outside of the submitted work.

Dr Zaman has reported travel, accommodation and expenses from Roche, Pierre Fabri and MSD Oncology, research funding from Roche/

Genentech consulting/advisory role for Roche, Eli Lilly, MSD Oncology, Mylan, Novartis, Daiichi and Pierre Fabre, and other relationships with Pierre Fabre, all outside the submitted work.

Dr Gligorov has declared speakers' bureau honoraria from Roche-Genentech, Novartis, Eisai, Genomic Health, Ipsen, Pfizer, Mylan, Eli Lilly, Sandoz, and Pierre-Fabre; consultant/advisory board member for Roche-Genentech, Novartis, Onxeo, Daiichi Sanyo, MSD, Eisai, Genomic Health, Ipsen, MacroGenics, Pfizer, Mylan, Eli Lilly, Immunomedics, Pierre-Fabre; grant support from Roche-Genentech, Eisai, Genomic Health, Pfizer, Mylan; travel, accommodation paid by Roche-Genentech, Novartis, Eisai, Genomic Health, Pfizer, Eli Lilly, Pierre-Fabre; personal fees and non-financial support from Daiichi Sanyo, MSD, outside of the submitted work.

Dr Awada reports advisory roles, travel grants, and speaker fees from Roche, Eli Lilly, Amgen, ESAI, BMS, Pfizer, Novartis, MSD, Ipsen, and Leopharma. Dr Campone has declared honoraria from Novartis, Eli Lilly, GT1, Consulting or Advisory Role from Novartis, Servier, Menarini, Sanofi, Eli Lilly, Pfizer, AstraZeneca/MedImmune, Abbvie, Pierre Fabre, Accord Healthcare, Sandoz-Novartis, Seattle Genetics, Daiichi Sankyo Europe GmbH, Speakers' Bureau from Novartis, Amgen, Research Funding from Novartis, Travel, Accommodations, Expenses from Novartis, AstraZeneca, Pfizer, Other Relationship from Roche, outside of the submitted work.

Dr Wildiers has declared Consulting or Advisory Role from Roche, Eli Lilly, Pfizer, Sirtex Medical, Orion Corporation, Puma Biotechnology, AstraZeneca, Biocartis, Novartis, Daiichi Sankyo, Research Funding from Roche, Novartis, Travel, Accommodations, Expenses from Pfizer, Roche, outside of the submitted work.

Dr Gennari has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, Eisai, and Daiichi Sankyo; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daiichi Sankyo; research funds from Eisai, Eli Lilly, and Roche, outside of the submitted work.

Dr Tjan-Heijnen has declared Honoraria and Travel expenses from Novartis, Roche, Eli Lilly, Pfizer and Honoraria from Daiichi Sankyo, as well as Research Funding from Roche, Eisai, Pfizer, Novartis, Eli Lilly, AstraZeneca and Daiichi Sankyo, outside of the submitted work.

Dr Cortes has declared **Stock and Other Ownership Interests from MedSIR, Honoraria from Novartis, Eisai, Celgene, Pfizer, Roche, Samsung, Eli Lilly, Merck Sharp & Dohme, Daiichi Sankyo, Consulting or Advisory Role from Celgene, Cellestia Biotech, AstraZeneca, Biothera, Merus, Roche, Seattle Genetics, Daiichi Sankyo, ERYTECH Pharma, Polyphor, Athenex, Eli Lilly, Servier, Merck Sharp & Dohme, GlaxoSmithKline, Leuko, Clovis Oncology, Bioasis, Boehringer Ingelheim, Research Funding from ARIAD, Astrazeneca, Baxalta, Bayer, Eisai, Guardant Health, Merck Sharp & Dohme, Pfizer, Puma Biotechnology, Queen Mary University of London, Roche, Piquir, Travel, Accommodations, Expenses from Roche, Pfizer, Eisai, Novartis, Daiichi Sankyo, outside of the submitted work.**

Dr Del Mastro acted as a consultant for Roche, Novartis, MSD, Pfizer, Ipsen, AstraZeneca, Genomic Health, Eli Lilly, Seattle Genetics, Eisai, Pierre Fabre, and Daiichi Sankyo, received speaker honoraria from Roche, Novartis, Eli Lilly and MSD, and travel grants from Roche, Pfizer and Celgene, outside the submitted work.

Dr Martin has declared Honoraria from Roche/Genentech, Eli Lilly, Pfizer, Novartis, Pierre Fabre, Consulting or Advisory Role from Roche/Genentech, Novartis, Pfizer, Eli Lilly, AstraZeneca, Taiho Pharmaceutical, PharmaMar, Speakers' Bureau from Eli Lilly/ImClone, Roche/Genentech, Pierre Fabre, Research Funding from Novartis, Roche, Puma Biotechnology, outside of the submitted work.

Dr Curigliano has reported personal fees from Roche, Pfizer, Novartis, Eli Lilly, Foundation Medicines, BMS, Samsung, Astra Zeneca, Daiichi Sankyo Boeringer, GSK, Seagen, non-financial support from Roche, Pfizer, grants from Merck, other from Ellipsis, outside the submitted work.

Dr Jerusalem has reported grants, personal fees and non-financial

support from Novartis, Roche and Pfizer, personal fees and non-financial support from Eli Lilly, Amgen, BMS and Astra-Zeneca, personal fees from Daiichi Sankyo and Abbvie, non-financial support from Medimmune and MerckKGaA, outside the submitted work.

Dr Prat reports grants and personal fees from Pfizer, grants and personal fees from Eli Lilly, personal fees from Nanostring technologies, grants and personal fees from Amgen, grants from Roche, personal fees from Oncolytics Biotech, Daiichi Sankyo, PUMA, BMS, consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer and Bristol-Myers Squibb and patent PCT/EP2016/080056, outside of the submitted work. Dr Prat is also an equity stockholder, founder and consultant of Reveal Genomics and has a patent HER2DX and WO 2018/103834 licensed to Reveal Genomics, all outside of the submitted work.

Dr Generali has declared Honoraria from Novartis and Eli Lilly, Research Funding from Novartis and Astra-Zeneca, outside of the submitted work.

All other authors declared nothing to disclose.

Data availability.

All data have been retrieved from already published papers.

Code availability.

No proprietary codes were used for the analyses reported in this study.

Acknowledgements

Dr F. Schettini is the recipient of an ESMO Fellowship – Translational and a BBVA Foundation – Hospital Clinic of Barcelona Joan Rodes – Josep Baselga Advanced Research Contract in Oncology. However, any views, opinions, findings, conclusions or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of Funders. This study was supported by MEDNotE, spin-off - University of Trieste, within the Mozart Program.

Funding

None.

Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ctrv.2022.102468>.

References

- [1] Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, et al. A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial. *Nat Med* 2018;24:628–37. <https://doi.org/10.1038/s41591-018-0009-7>.
- [2] Gong Y, Liu Y-R, Ji P, Hu X, Shao Z-M. Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. *Sci Rep* 2017;7:45411. <https://doi.org/10.1038/srep45411>.
- [3] Hartman A-R, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. *Cancer* 2012;118(11):2787–95.
- [4] Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018;379(8):753–63.
- [5] Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017;377(6):523–33.
- [6] Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. *JCO* 2020;38(15 suppl):1000.
- [7] Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. *N Engl J Med* 2018;379(22):2108–21.
- [8] Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B, Ramkissoon S, et al. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. *J Immunother Cancer* 2020;8(2):e001558.
- [9] Mittendorf EA, Phillips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. *Cancer Immunol Res* 2014;2:361–70. <https://doi.org/10.1158/2326-6066.CIR-13-0127>.
- [10] National Comprehensive Cancer Network. NCCN Guidelines for Breast Cancer, vers.4.2022 n.d. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed June 28, 2022).
- [11] Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. *Ann Oncol* 2021;32(12):1475–95.
- [12] Bardia A, Mayer IA, Vahdat LT, Tolanev SM, Isakoff SJ, Diamond JR, et al. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. *N Engl J Med* 2019;380(8):741–51.
- [13] Bardia A, Hurvitz SA, Tolanev SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *N Engl J Med* 2021;384(16):1529–41.
- [14] Schettini F, Chic N, Brasó-Maristany F, Paré L, Pascual T, Conte B, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. *npj Breast Cancer* 2021;7(1). <https://doi.org/10.1038/s41523-020-00208-2>.
- [15] Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. *N Engl J Med* 2022;387(1):9–20.
- [16] Egger SJ, Chan MMK, Luo Q, Wilcken N. Platinum-containing regimens for triple-negative metastatic breast cancer. *Cochrane Database Syst Rev* 2020;10:CD013750. <https://doi.org/10.1002/14651858.CD013750>.
- [17] Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, et al. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update. *JCO* 2021;39(35):3938–58.
- [18] Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. *Value Health* 2011;14(4):417–28.
- [19] Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. *Value Health* 2011;14(4):429–37.
- [20] Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol* 2019;20(10):1360–9.
- [21] Li L, Pan Z. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials. *Clin Breast Cancer* 2018;18:63–70. <https://doi.org/10.1016/j.clbc.2017.07.015>.
- [22] Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, et al. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. *Breast Cancer Res Treat* 2015;152(1):95–117.
- [23] Diéras Véronique, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub J-P, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2020;21(10):1269–82.
- [24] Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMPassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann Oncol* 2021;32(8):994–1004.
- [25] Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. *The Lancet* 2020;396(10265):1817–28.
- [26] Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2021;22(4):499–511.
- [27] Kim S-B, Dent R, Im S-A, Espié M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol* 2017;18(10):1360–72.
- [28] Dent R, Kim S-B, Oliveira M, Barrios C, O’Shaughnessy J, Isakoff SJ, et al. Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A. *Cancer Res* 2021;81:GS3-04. <https://doi.org/10.1158/1538-7445.SABCS20-GS3-04>.
- [29] Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, et al. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. *J Clin Oncol* 2020;38(5):423–33.

- [30] Harbeck N, Saupé S, Jäger E, Schmidt M, Kreienberg R, Müller L, et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. *Breast Cancer Res Treat* 2017;161(1):63–72.
- [31] von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014;15(11):1269–78.
- [32] Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, et al. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. *Lancet Oncol* 2016;17(1):90–8.
- [33] Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility. *Statist Comput* 2000;10:325–37. <https://doi.org/10.1023/A:1008929526011>.
- [34] Mbuagbaw L, Rochweg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. *Syst Rev* 2017;6:79. <https://doi.org/10.1186/s13643-017-0473-z>.
- [35] Gelman A, Rubin D. Inference from iterative simulation using multiple sequences. *Statist Sci* 1992;7:457–511.
- [36] Lynch SM. Introduction to Applied Bayesian Statistics and Estimation for Social Scientists. In: Lynch SM, editor. *Introduction to Applied Bayesian Statistics and Estimation for Social Scientists*. New York, NY: Springer New York; 2007. p. 1–7.
- [37] Dias S, Ades A, Welton N, Jansen J, Sutton A. *Network Meta-Analysis for Decision-Making* | Wiley. 1st Edition. John Wiley and Sons; 2018.
- [38] Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162(11):777–84.
- [39] Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. *Res Synth Methods* 2012;3:98–110. <https://doi.org/10.1002/jrsm.1044>.
- [40] Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. *Stat Med* 2010;29:932–44. <https://doi.org/10.1002/sim.3767>.
- [41] R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. n.d.
- [42] Higgins J, Green S. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; n.d.
- [43] Miles D, Gligorov J, André F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMPassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. *Ann Oncol* 2021;32(8):994–1004.
- [44] Delaloue S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. *Ann Oncol* 2016;27(9):1725–32.
- [45] Dieras V, Pop S, Berger F, Dujaric M-E, Beuzeboc P, Escalup L, et al. First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. *Anticancer Res* 2017;37:1403–7. <https://doi.org/10.21873/anticancer.11462>.
- [46] Smith IE, Pierga J-Y, Biganzoli L, Cortés-Funes H, Thomssen C, Pivrot X, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. *Ann Oncol* 2011;22(3):595–602.
- [47] Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, et al. Efficacy of biological agents in metastatic triple-negative breast cancer. *Cancer Treat Rev* 2014;40(5):605–13.
- [48] Miles DW, Diéras V, Cortés J, Duenne A-A, Yi J, O'Shaughnessy J. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. *Ann Oncol* 2013;24:2773–80. <https://doi.org/10.1093/annonc/mdt276>.
- [49] Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *Ann Oncol* 2016;27:v119–33.
- [50] Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. *Ann Oncol* 2016;27:v111–8.
- [51] Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Gaspy J, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. *Ann Oncol* 2018;29:iv96–110.
- [52] Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, et al. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. *Front Oncol* 2021;11. <https://doi.org/10.3389/fonc.2021.686776>.
- [53] Tung NM, Robson ME, Venz S, Santa-Maria CA, Nanda R, Marcom PK, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *J Clin Oncol* 2020;38(36):4274–82.
- [54] Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). *Ann Oncol* 2021;32(1):49–57.
- [55] Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. *Eur J Cancer* 2021;149:134–52.
- [56] Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. *N Engl J Med* 2021;384(25):2394–405.
- [57] Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. *Annals of Oncology* 2021;0. <https://doi.org/10.1016/j.annonc.2021.06.014>.
- [58] Roche Group Media Relations. Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer. Roche Media Releases n.d. <https://www.roche.com/media/releases/med-cor-2021-08-27.htm> (accessed October 18, 2021).
- [59] Rugo H, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, et al. Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or m.... *Cancer Research* 2021;81:OT-30-01-OT-30-01. <https://doi.org/10.1158/1538-7445.SABCS20-OT-30-01>.
- [60] Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerrataana L, Tell G, et al. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. *Int J Mol Sci* 2019;20(14):3390.
- [61] Schmid P, Cortes J, Robson ME, Iwata H, Hegg R, Nechaeva M, et al. A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPitello290). *JCO* 2020;38(15_suppl):TP51109.
- [62] Therapeutics G. G1 Therapeutics Announces Initiation of Phase 3 Registration Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC). GlobeNewswire News Room 2021. <https://www.globenewswire.com/news-release/2021/04/28/2218475/0/en/G1-Therapeutics-Announces-Initiation-of-Phase-3-Registration-Study-of-COSELA-trilaciclib-in-Triple-Negative-Breast-Cancer-TNBC.html> (accessed June 2, 2021).
- [63] Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. *Cancer Treat Rev* 2016;50:129–41. <https://doi.org/10.1016/j.ctrv.2016.09.004>.
- [64] Puglisi F, Rea D, Kroes MA, Pronzato P. Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review. *Cancer Treat Rev* 2016;43:36–49. <https://doi.org/10.1016/j.ctrv.2015.11.012>.
- [65] Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol* 2020;38(1):1–10.
- [66] Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol* 2020;21(10):1353–65.
- [67] Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G, Haibe-Kains B. Graphical Tools for Network Meta-Analysis in STATA. *PLoS ONE* 2013;8(10):e76654.
- [68] Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. *J Clin Oncol* 2021;39(35):3959–77.
- [69] Bailar JC. The promise and problems of meta-analysis. *N Engl J Med* 1997;337(8):559–61.
- [70] Greenland S. Can meta-analysis be salvaged? *Am J Epidemiol* 1994;140:783–7. <https://doi.org/10.1093/oxfordjournals.aje.a117326>.
- [71] Chaimani A, Caldwell D, Li T, Higgins J, Salanti G. Chapter 11: Undertaking network meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook. n.d.
- [72] Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making* 2013;33:607–17. <https://doi.org/10.1177/0272989X12458724>.
- [73] Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, et al. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. *Cancers (Basel)* 2021;13(17):4421.